Adisseo, Novozymes launch probiotic additive Alterion

After four years of work on the product, Adisseo and Novozymes are launching a feed additive product, Alterion, they say can work as a natural alternative to growth-promoting antibiotics being phased out of livestock feed around the world.

Austin 70x70 Headshot
adisseo-breakfast-ippe

After four years of work on the product, Adisseo and Novozymes are launching a feed additive product, Alterion, they say can work as a natural alternative to growth-promoting antibiotics being phased out of livestock feed around the world.

On January 27, representatives of the French feed additives company announced the launch of the probiotic additive during a breakfast event at the International Production & Processing Expo in Atlanta. Dr. Stefan Jakob, director of innovation projects for Adisseo, introduced the probiotic and explained its benefits for broiler producers.

Alterion is a proprietary strain of Bacillus subtillis developed as part of a collaboration product between Adisseo and the Danish biotechnology company. It allows farmers to better control gut health of their animals, limits development of unwanted bacteria in the digestive tract, and optimizes feed conversion by 2 to 2.5 percent.

Jakob said the product was developed as a response to regulatory and consumer preferences that are driving farmers away from using antibiotics. In 2017, the U.S. Food and Drug Administration’s Veterinary Feed Directive will prohibit the use of growth-promoting antibiotics in animal feed. The products have been banned in the European Union since 2006.

Alterion, Jakob said, will help provide continuity to U.S. farmers who don’t want to lose productivity as a result of the ban.

“We have the next-generation probiotic for the market with a true dual action (of) performance and gut health improvement, for a consistently successful broiler production,” Jakob said.

Gut health is key, he said, because poultry diseases like necrotic enteritis caused by Clostridium perfringens, and other pathogenic bacteria, contribute to $6 billion in annual losses in the global poultry industry. Research conducted by the companies shows the product is more effective than competing Bacillus subtillis products in both healthy and clostridium-infected birds.

The product is being released in the U.S. as well as several  countries in the Middle East and Southeast Asia.

Adisseo is a subsidiary of Chinese chemical company China National BlueStar Co. Ltd.

Page 1 of 5
Next Page